Introduction
early-stage favorable disease, Hodgkin lymphoma, CMT, HL
REMISSION, HODGKIN LYMPHOMA
Since long-term remission rates for Hodgkin lymphoma (HL) patients with early-stage favorable disease are already above 90% after combined modality first-line therapy (CMT) [A widely used standard of care for early-stage favorable HL is treatment with two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by 20 Gy involved-site radiotherapy (RT). However, the RT consolidation within the CMT concept is assumed to be more harmful than the chemotherapy [